[HTML] The non‐peptide GLP‐1 receptor agonist WB4‐24 blocks inflammatory nociception by stimulating β‐endorphin release from spinal microglia
H Fan, N Gong, TF Li, AN Ma, XY Wu… - British journal of …, 2015 - Wiley Online Library
Background and Purpose Two peptide agonists of the glucagon-like peptide-1 (GLP-1)
receptor, exenatide and GLP-1 itself, exert anti-hypersensitive effects in neuropathic, cancer
and diabetic pain. In this study, we have assessed the anti-allodynic and anti-hyperalgesic
receptor, exenatide and GLP-1 itself, exert anti-hypersensitive effects in neuropathic, cancer
and diabetic pain. In this study, we have assessed the anti-allodynic and anti-hyperalgesic
For custom peptides, please visit www.pepmic.com. Our peptide services including but not limited to:
*Peptide Synthesis: From short peptides to long peptides, linear peptides to cyclic peptides.
*Peptide Modifications: Peptide-protein conjugation, D-amino acid peptides, isotope peptides, fluorescent peptides, multiple antigen peptides, multiple disulfide bridge peptides, phosphopeptides etc.
*Catalog Peptides: ACE Inhibitors, Amyloids & Related Peptides, Antimicrobial Peptides, Apelin Peptides, Myelin Oligodendrocyte Glycoprotein (MOG) Peptides, TAT Proteins etc.
*Peptide Salt: TFA, Desalt, Acetate, HCl.
*Peptide Purity: From crude to >99.5%.
*Production Capacity: From mg to kg, with a capacity of synthesizing 15,000 peptides/month.
*Peptide Library Synthesis: Alanine Scan, Overlapping, Positional Scan, T-cell Truncated, Scrambled ect.
Quick Links:
Contact Information:
Eva He
eva@pepmic.com
Pepmic Co., Ltdeva@pepmic.com
www.pepmic.com
没有评论:
发表评论